The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Open accessAbstract
BACKGROUND: High plasma levels of nonfasting triglycerides are associated with an increased risk of ischemic cardiovascular disease. Whether lifelong low levels of nonfasting triglycerides owing to mutations in the gene encoding apolipoprotein C3 (APOC3) are associated with a reduced risk of ischemic cardiovascular disease in the general population is unknown. METHODS: Using data from 75,725 participants in two general-population studies, we first tested whether low levels of nonfasting triglycerides were associated with reduced risks of ischemic vascular disease and ischemic heart disease. Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease. During follow-up, ischemic vascular disease developed in 10,797 participants, and ischemic heart disease developed in 7557 of these 10,797 participants. RESULTS: Participants with nonfasting triglyceride levels of less than 1.00 mmol per liter (90 mg per deciliter) had a significantly lower incidence of cardiovascular disease than those with levels of 4.00 mmol per liter (350 mg per deciliter) or more (hazard ratio for ischemic vascular disease, 0.43; 95% confidence interval [CI], 0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI, 0.31 to 0.52). Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001). The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04). CONCLUSIONS: Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. (Funded by the European Union and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [171]
The cited source says what the claim attributes to it.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Low-density lipoprotein (LDL) cholesterol and triglyceride-rich remnant lipoproteins are causally associated with risk of atherosclerotic vascular disease [3][4][5][6]”
From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [4]
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“Some rare heterozygous loss-of-function (LOF) variants are associated with reduced TG levels. These patients show protection from ASCVD providing important evidence for a causal role of TG for ASCVD.”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Such LOF variants of APOC3 are also associated with reduced ASCVD risk.10”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.86,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Pre-mRNA splicing and human diseasePreprint
Faustino, N. A., & Cooper, T. A. (2003) · Genes & Development · doi:10.1101/gad.1048803 · Cited by 1,248
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 801–900 of 923
Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say
Kei, A. A., & Elisaf, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12762 · Cited by 1
JCL roundtable: Lessons from genetic variants altering lipoprotein metabolism
Brown, W. V., Ference, B. A., & Kathiresan, S. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.002 · Cited by 1
The Advent of High-Throughput Sequencing Studies of Chronic Obstructive Pulmonary Disease
Ortega, V. E., & Celedon, J. C. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0074ed · Cited by 1
Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases
Swerdlow, D. I., Michail, M., & Zacharias, K. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00008-2 · Cited by 2
Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders
Lee, J.-H., & Hegele, R. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1311784 · Cited by 1
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 2
Therapie der diabetischen Dyslipidämie
Brandts, J., & Lebherz, C. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0362-7 · Cited by 1
Chatterjee, S. (2018) · Diabetes and Islet Biology · doi:10.31579/2641-8975/003 · Cited by 1
Stryukova, E. V., Maksimov, V. N., Ragino, Y. I., Polonskaya, Y. V., Murashov, I. S., Волков, А. М., Кургузов, А. В., Chernjavskii, A. M., & Kashtanova, E. V. (2020) · Meta Gene · doi:10.1016/j.mgene.2020.100847 · Cited by 1
Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins
Kachkovsky, M. A., Vvedenskaya, I. P., Vvedensky, V. Y., Supilnikov, A. A., Ponomareva, J. V., & Milyakova, M. N. (2020) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2020.4.11 · Cited by 1
Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management
Cupido, A. J., Stoekenbroek, R. M., & Kastelein, J. J. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-44203-7_21 · Cited by 1
Personalized Therapy of Cardiovascular Disorders
Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_13 · Cited by 1
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Atherosclerosis is the outcome of adaptive complexity in the Arterial Endothelial Microenvironment
Roy, T., Ray, A. G., & Bandyopadhyay, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00081-5 · Cited by 1
Treating Cardiovascular Disorders with Personalized Medicine
Garg, I., Kumar, H., Verma, M., Chauhan, I., & Panwar, V. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x361429250215190129 · Cited by 2
Safely lowering triglycerides through ANGPTL4 inhibition
Wulff, A. B. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00988-2 · Cited by 1
Basics in Lipoprotein Metabolism
Yassine, H. N., Tappin, K., & Sethi, M. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-11161-2_1 · Cited by 1
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1
Genetics and Valve Calcification ∗
Brown, W. V. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.048 · Cited by 1
Sinning, D., & Landmesser, U. (2017) · Herz · doi:10.1007/s00059-017-4601-2 · Cited by 1
Chen, H., Wu, M., Jiang, W., Liu, X., Zhang, J., & Yu, C. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4472 · Cited by 1
Rohatgi, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00008-x · Cited by 1
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 2
Libby, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00005-0 · Cited by 1
Mendelian Randomisation: A MinireviewPreprint
Wells, D. (2017) · doi:10.22541/au.149652750.03402000 · Cited by 1
From the Editor: New guidelines are coming
Brown, W. V. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.011 · Cited by 1
Lotta, L. A., Dong, L., Li, C., Patel, S., Stewart, I. D., Lim, K., Day, F. R., Wheeler, E., Glastonbury, C. A., de Streek, M. V., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/372128 · Cited by 2
Role of Rare and Low Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid LevelsPreprint
Wang, Z., Chen, H., Bartz, T. M., Bielak, L. F., Chasman, D. I., Feitosa, M. F., Franceschini, N., Guo, X., Lim, E., Noordam, R., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/561225 · Cited by 1
Rodríguez, M. M., Rehues, P., Iranzo, V., Mora, J. D., Balsells, C., Guardiola, M., & Ribalta, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.15.298802 · Cited by 1
Stankov, S. G., Vitali, C., Park, J., Nguyen, D., Mayne, L. C., Englander, S. W., Levin, M. G., Vujković, M., Hand, N. J., Phillips, M. C., et al. (2023) · medRxiv · doi:10.1101/2023.02.21.23286268 · Cited by 1
Systemic inflammation is a minor contributor to remnant cholesterol atherogenicityPreprint
Kraaijenhof, J. M., Kerkvliet, M., Nurmohamed, N. S., Grefhorst, A., Kroon, J., Wareham, N. J., Hovingh, G. K., Stroes, E. S. G., Boekholdt, S. M., & Reeskamp, L. F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.18.604203 · Cited by 1
Plozasiran and Apolipoprotein C-III Inhibition
Schwartz, G. G., & Cobbaert, C. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.519 · Cited by 1
Apolipoprotein C3 and cardiovascular risk: new insights from the ODYSSEY outcomes trial
Catapano, A. L., Pirillo, A., & Tokgözoğlu, L. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf202 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Stock, J. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.039
Genetic and metabolic studies of APOE, PCSK9, TM6SF2 and PNPLA3
Mahdessian, H. (2014) · Figshare
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Biomarker des Lipoproteinstoffwechsels
von Eckardstein, A. (2015) · Cardiovascular Medicine · doi:10.4414/cvm.2015.00297
Hypertriglyceridemia: Should We Treat?
Brinton, E. A. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch27
Aktuelle Lipidtherapie bei Diabetes mellitus
Lebherz, C. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0068-7
Mendel, Molecular Biology, and Apolipoprotein C-III: A Heady Combination
Patel, S. B. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.1506
Amati, F., & Widmann, C. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000118
Zufallsbefund Hypertriglyzeridämie
Parhofer, K. G. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-2917-5
Identification of genetic modifiers in LRRK2 parkinsonism
Trinh, J. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0340339
West, G. (2017) · OpenCommons - UConn (University of Connecticut)
The shape of things to come in lipid management: a feast of reason
Watts, G. F., & Stroes, E. S. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000467
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
VII. Triglyceride and HDL Cholesterol as Risk Factors and the Treatment Targets for Atherosclerosis
Ai, M. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.725
Lackner, K. J., & Peetz, D. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_268
Åvall, K., Berggren, P., & Juntti‐Berggren, L. (2018) · Laboratory Animal Research · doi:10.5625/lar.2018.34.3.126
Watts, G. F., & Stroes, E. S. G. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000560
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke
Sullivan, D., Bonnitcha, P., Spinks, C., & Keech, T. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002247
Гиляревский, С. Р., Kuzmina, I. M., Golshmid, M. V., & Юрьевна, З. Г. (2016) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2016-2-98-105
Regulation of Lipoprotein Lipase Activity : an In-vitro Study of a Complex and Dynamic System
Kovrov, O. (2019) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Dissecting the role of apolipoprotein CIII in diabetic wound healing
Cho, M. M. W. (2019) · doi:10.32657/10220/48515
Choosing a genome editing strategy and target site
Musunuru, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823484-6.00011-6
Björnson, E. (2021) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Durlach, V. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-76753-1.00048-5
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_6075
Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management
Cupido, A. J., Stoekenbroek, R. M., & Kastelein, J. J. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-45457-9_23
Quispe, R., Das, T. M., & Michos, E. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_2
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_6075-1
Lackner, K. J., & Peetz, D. (2018) · Springer eBooks · doi:10.1007/978-3-662-49054-9_270-1
Elkin, R. L., & Krasuski, R. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000151
Biomarkers of Cardiovascular Disorders
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7431-3_15
Lackner, K. J., & Peetz, D. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_270
Har HDL-kolesterol og triglyserider en rolle i hjerte- og karsykdom?
Christensen, J. J. (2015) · Norsk tidsskrift for ernæring · doi:10.18261/ntfe.13.4.7
Icosapent Ethyl for the Prevention of Cardiovascular Events
Lloyd, J. (2019) · EMJ Cardiology · doi:10.33590/emjcardiol/10311840
Hussain, A., & Ballantyne, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00028-5
Catapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00013-3 · Cited by 1
Ginsberg, H. N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00031-5
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Targeting microbial biofilms using genomics-guided drug discovery
Chakravarty, D., Bhattacharya, D., Ganguli, S., & Ghosh, U. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95715-1.00020-0
He, Y., Yao, F., Pan, L., Cao, D., Wang, Q., Huang, T., Wang, J., Xie, Y., Li, X., Liu, Q., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3547892/v1
Li, J., Sun, H., Wang, Y., Liu, J., & Wang, G. (2023) · Figshare · doi:10.6084/m9.figshare.22613807
Li, J., Sun, H., Wang, Y., Liu, J., & Wang, G. (2023) · Figshare · doi:10.6084/m9.figshare.22613810
Labordiagnostik von Fettstoffwechselstörungen
März, W., Scharnagl, H., Kleber, M. E., Silbernagel, G., Nauck, M., Müller‐Wieland, D., & von Eckardstein, A. (2024) · Diabetes aktuell · doi:10.1055/a-2302-8505
Einsatz von Olezarsen bei Hypertriglyzeridämie und familiärem Chylomikronämiesyndrom
Leitolf, H., & Nitschmann, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01785-1
Moury, J., Nendumba, G., Robert, A., Hauqiert, B., Vornicu, O., Blackman, S., Perriens, E., Bendoumou, M., Sánchez, A., Buttice, E., et al. (2024) · Annals of Translational Medicine · doi:10.21037/atm-24-63
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752
Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering
Gagnon, É., & Arsenault, B. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000977
Outland, E. H., Xin, Y., Dickson, A. L., Mundo, S., Tao, R., Zhong, X. Y., Karakoc, G., Serley, S., Jiang, L., Cox, N. J., et al. (2025) · medRxiv · doi:10.1101/2025.03.07.25323588
Duell, P. B. (2025) · International Journal of Clinical and Translational Medicine · doi:10.53941/ijctm.2025.100008
Loss-of-Function in APOC3 and Protection Against Aortic Valve Disease
Bourgault, J., Wulff, A. B., Houessou, U., Manikpurage, H. D., Clavel, M.-A. A., Pîbarot, P., Bossé, Y., Mathieu, P., Tybjærg‐Hansen, A., Thériault, S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.028
Self-citationApolipoproteins in the context of lipoprotein metabolism
Labanczová, M. (2023) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2023.030
Zhang, Q., & Yu, Z. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s532542 · Cited by 1
Exonic Variation and Its Clinical Impact in 7221 Old Order Amish
Mitchell, B. D., Onyenobi, E., Lewis, J. P., Gaynor, B. J., Perry, J. A., Maloney, K. A., O’Connell, J. R., Tiner, J. C., Beitelshees, A. L., Hout, C. V. V., et al. (2025) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.64212
Martins, Y. A., Schultz, C., Rodrigues, N., Ravanelli, M. I. B., Visentainer, J. V., Santos, O. D. O., Berti, J. A., & Brunaldi, K. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152715
Olezarsen in moderate hypertriglyceridemia: The Essence-TIMI 73b trial
Gouni‐Berthold, I. (2025) · Med · doi:10.1016/j.medj.2025.100923
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Additional file 1 of Apolipoprotein C-III in patients with systemic lupus erythematosus
Martín‐González, C., Ferrer‐Moure, C., Carlos Quevedo-Abeledo, J., de Vera-González, A., Delgado, A. G., Sánchez-Martín, J., González-Gay, M. Á., & Ferraz-Amaro, I. (2022) · Figshare · doi:10.6084/m9.figshare.19745339
Goyal, S., Tanigawa, Y., Zhang, W., Chai, J.-F., Almeida, M., Sim, X., Lerner, M., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16655697
Li, W., Wang, Y., 黄日太, Feng, L., Xu, G., Wang, W., & Xue, S. (2024) · Figshare · doi:10.6084/m9.figshare.25200728
Li, W., Wang, Y., 黄日太, Feng, L., Xu, G., Wang, W., & Xue, S. (2024) · Figshare · doi:10.6084/m9.figshare.25200645
Sandholm, N., Hotakainen, R., Haukka, J. K., Sigfrids, F. J., Dahlström, E. H., Antikainen, A. A., Valo, E., Syreeni, A., Kilpeläinen, E., Kytölä, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21622433
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Figshare · doi:10.6084/m9.figshare.12401108
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Figshare · doi:10.6084/m9.figshare.12401099
Li, W., Wang, Y., 黄日太, Feng, L., Xu, G., Wang, W., & Xue, S. (2024) · Figshare · doi:10.6084/m9.figshare.26679272
Feroz, K., Parvez, A., Ramzan, N. U. H., Asghar, T., Cheema, A. H., Malik, A. P., Fatima, T., Iqbal, J., & Sathian, B. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/9984822
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Self-citation
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 32-41
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2052644460
- Semantic Scholar
- 55f5e169d6f4d9a568cca4bbafe0790022e8bc16
- Cited by
- 919
- References
- 39
- Citations by year
- 2026: 50 · 2025: 76 · 2024: 49 · 2023: 46 · 2022: 65 · 2021: 64 · 2020: 95 · 2019: 71 · 2018: 71 · 2017: 99 · 2016: 113 · 2015: 87 · 2014: 32
- FWCI
- 75.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Gentofte Hospital
- Rigshospitalet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, ischemic vascular disease, ischemic heart disease, cardiovascular risk, heterozygosity, genetic variants, triglyceride lowering, general population, hypertriglyceridemia, genetic epidemiology, Mendelian randomization
- MeSH terms
- Adult, Aged, Female, Genotype, Humans, Ischemia, Cholesterol, LDL, Liver, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Incidence, Myocardial Ischemia, Sequence Analysis, DNA, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
